It is nothing new, because doctors have been warning us of infections of the antibiotic resistant bacteria. This, added to the fact that there are companies that no longer see the need to manufacture antibiotics, then we will not be able to treat such infections. What will happen?
Edith Heard, director of the European Molecular Biology Laboratory (EMBL), in an interview with El País, commented that the Covid-19 pandemic was something they could see years ago.
What’s more, he comments in this interview that two years ago, before the pandemic, they knew there was a risk, “Because we knew other viruses like SARS. We need molecular tools to understand what is happening. We knew that these matters were very urgent. And then the pandemic arrived ”.
Coupled with this, the expert is concerned about the rapid growth of resistance to antibiotics. Something that many doctors already warned about a long time ago and now things are even more complicated.
This is why many scientists are directing their studies to try to answer why this happens and prevent such a problem that could establish itself in a new pandemic soon.
Head is blunt and believes that in 10 to 20 years we will be dying from infections of bacteria resistant to antibiotics. And this is because they cannot be treated. It establishes that a few years the current antibiotics will not be able to treat the infections that we will have.
What must we do to stop this possible epidemic?
Scientists see that, to stop this growing problem, epigenetics must be studied. For what you want to get epigenetic drugs to stop this possible new pandemic.
In the interview, Edith Heard explains that the genome is made of DNA. In cancer, if you have a mutation that affects the DNA, it is already there, you cannot undo it. But it has been known for years that some changes are not found at the DNA level, but at an epigenetic level.
Apparently, when it comes to cancer, it has been discovered that there are epigenetic changes, not just genetic. And this can be changed with an epigenetic drug that is capable of change epigenetic modifications.
The expert acknowledges that epigenetic drugs are already being used, but a few years ago she thought that everything would go faster. And this changes according to each type of cancer. Well, the expert comments that, for example, for certain forms of leukemia there are some drugs, but in the field of solid tumors, such as lung cancer, less progress has been made.